National Healthcare Agreement: PB c–Better health: reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023, 2016

Collection and usage attributes

Proxy measure:

The National Health Measures Survey component of the 2011–13 Australian Health Survey (cat. no. 4364.0.55.005) included a fasting plasma glucose test.

A respondent to the survey is considered to have known diabetes if they had ever been told by a doctor or nurse that they have Type 2 diabetes and:

• They were taking diabetes medication (either insulin or tablets); or
• Their blood test result for fasting plasma glucose was greater than or equal to 7.0 mmol/L).

A respondent to the survey is considered to have newly diagnosed diabetes if they reported no prior diagnosis of diabetes, but had a fasting plasma glucose value greater than or equal to 7.0 mmol/L.

Excludes persons who did not fast for 8 hours or more prior to their blood test.

Excludes women with gestational diabetes.

Population is limited to persons aged 25 years and over.

Rates are directly age-standardised to the 2001 Australian population.

Analysis by remoteness and Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage (IRSD) is based on usual residence of person (subject to data availability).

Presented as a percentage.

95% confidence intervals and relative standard errors calculated for rates.

Note: The type of diabetes for newly diagnosed cases cannot be determined from a fasting plasma glucose test alone.  However, it is assumed that the vast majority of newly diagnosed cases would be Type 2.

100 x (numerator/denominator)

Number of persons aged 25 years and over with known diabetes (Type 2) or newly diagnosed diabetes as determined by a fasting plasma glucose test.

Population aged 25 years and over.

State and territory, by:

• sex
• Indigenous status (non-Indigenous only).

Nationally, by:

• remoteness (Australian Statistical Geography Standard (ASGS) Remoteness Structure)
• 2011 SEIFA IRSD quintiles.

State and territory by Indigenous status (Indigenous only).

Some disaggregations may result in numbers too small for publication.

Most recent data available for 2016 National Healthcare Agreement performance reporting: 2011–12 (total population, non-Indigenous: AHS); 2012–13 (Indigenous only: AATSIHS).

NO NEW DATA FOR 2016 REPORTING.

The baseline measure of 7.1 per cent is calculated from the Australian Diabetes, Obesity and Lifestyle Study conducted in 1999–2000. Note that this number was age-standardised to the average of the 1999 and 2000 Australian populations, and was based on data from both oral glucose tolerance tests (OGTTs) and fasting plasma glucose tests. As an OGTT was not conducted as part of the National Health Measures Survey, the data supplied for the 2014 CRC report are not comparable to the baseline measure of 7.1 per cent.

Fasting plasma glucose test data will be supplied as a proxy from the AHS for this benchmark, age-standardised to the 2001 Australian population.  The equivalent baseline measure from the Australian Diabetes, Obesity and Lifestyle Study, age-standardised to the 2001 Australian population and using fasting plasma glucose test data, has been calculated to be a rate of 5.0%.

Representational attributes

Indicator conceptual framework

Data source attributes

Accountability attributes

National Healthcare Agreement

Australian Bureau of Statistics

National Healthcare Agreement Performance Benchmark

Reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023.

Refer: http://www.federalfinancialrelations.gov.au/content/npa/healthcare/
national-agreement.pdf

Specification: Final, the measure meets the intention of the indicator.

Source and reference attributes

Relational attributes